 Home > Medical News > Latest Medical News > Announcement of Phase Ib clinical results of sintilimab combined with bevacizumab in the treatment of advanced hepatocellular carcinoma

Announcement of Phase Ib clinical results of sintilimab combined with bevacizumab in the treatment of advanced hepatocellular carcinoma

 Last Update: 2022-02-18
 Source: Internet
 Author: User

Tags

risperidone 5 mg

aqueous phase

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Innovent and Eli Lilly jointly announced the final clinical study results and biomarker analysis of Dabosu® (sintilimab injection) in combination with bevacizumab in the treatment of advanced hepatocellular carcinoma (NCT04072679) in Phase Ib (NCT04072679).

The study is a Phase Ib trial (NCT04072679) evaluating the safety, tolerability and antitumor activity in Chinese patients with locally advanced/metastatic hepatocellular carcinoma who have not or failed systemic therapy.

In terms of efficacy, the overall objective response rate (ORR) was 34% (17/50), with ORRs of 31% and 38% in the low-dose and high-dose groups, respectively

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Innovent and Eli Lilly will jointly announce final clinical results and biomarker analysis of the Phase Ib study of Dabosu (sintilimab injection) combined with bevacizumab in the treatment of advanced hepatocellular carcinoma at ASCO GI in 2022 result

02-18

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Announcement of Phase Ib clinical results of sintilimab combined with bevacizumab in the treatment of advanced hepatocellular carcinoma

Related Articles

Innovent and Eli Lilly will jointly announce final clinical results and biomarker analysis of the Phase Ib study of Dabosu (sintilimab injection) combined with bevacizumab in the treatment of advanced hepatocellular carcinoma at ASCO GI in 2022 result